Impact of sodium‒glucose cotransporter‐2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis
Pooled result · HF hospitalizationResult — go to the resultRelative risk 0.77 95% CI 0.69–0.85Authors' conclusion
In this meta-analysis of patients who experienced MI, the administration of SGLT2 inhibitors was associated with lower rates of hospitalization for HF. In addition, the treatment effect of SGLT2 inhibitors was consistent regardless of whether they were started in the recent versus previous MI setting.
Study context
- Population
- Patients with recent or previous myocardial infarction (MI) in RCTs; 51.2% with T2D, mean age 62 years
- Participants
- 22,266 patients10 RCTs
- Comparison
- SGLT2i vs placebo in patients with MI
- Outcome
- HF hospitalization
- Follow-up
- Median 21 months
Methodological detailsrandom effects model
- Random effects model
Pooled result
As reported in the abstract
Relative risk
0.77
95% CI 0.69–0.85
P < 0.001
SGLT2ivs Placebo
RR 0.77 (95% CI 0.69–0.85); P < 0.001
Further pooled results
| Outcome | RR (95% CI) | P value | |
|---|---|---|---|
| MACE (CV death, MI or stroke)SGLT2ivs Placebo | 0.88 (0.79–0.97) | P = 0.012 | |
| All-cause mortalitySGLT2ivs Placebo | 0.88 (0.78–1.00) | P = 0.058 | |
| 0.512Relative risk (log scale) |
Heart failure (HF) hospitalization by timing of MI (previous MI >8 weeks vs acute MI ≤8 weeks)
- Benefit consistent regardless of timing of last MI; no treatment by subgroup interaction
- P for interaction = 0.56
Original publication
Impact of sodium‒glucose cotransporter‐2 inhibitors in patients with recent versus previous myocardial infarction: a systematic review and meta-analysis. Cardiovasc Diabetol. Published 13 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →